Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
RUT
Market Cap
64.66M
Enterprise Value
-49.07M
Income
-65.76M
Sales
0.00M
Book/sh
2.39
Cash/sh
2.50
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
16
IPO
Apr 04, 1994
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.60
P/C
0.57
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
14.01
Current Ratio
14.01
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-1.39
EPS next Y
-1.31
EPS next Q
-0.36
EPS this Y
-3.70%
EPS next Y
5.89%
EPS next 5Y
1.50%
EPS past 3/5Y
86.93% 77.09%
Sales past 3/5Y
- -
EPS Y/Y TTM
-22.58%
Sales Y/Y TTM
-
EPS Q/Q
21.42%
Sales Q/Q
-
Insider Own
9.48%
Insider Trans
-
Inst Own
76.78%
Inst Trans
10.39%
ROA
-59.83%
ROE
-64.20%
ROIC
-60.52%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-16.10%
SMA50
-19.30%
SMA200
-84.62%
Trades
Shs Outstand
45.54M
Shs Float
41.22M
52W High
19.40 -92.68%
52W Low
1.31 8.40%
Volatility
6.67% 8.09%
ATR (14)
0.13
RSI (14)
33.42
Beta
1.01
Rel Volume
0.01
Avg Volume
3.55M
Volume
963
Perf Week
-15.98%
Perf Month
-12.88%
Perf Quarter
-20.22%
Perf Half Y
-88.17%
Perf YTD
-88.35%
Perf Year
-81.52%
Perf 3Y
-95.34%
Perf 5Y
-99.93%
Perf 10Y
-100.00%
Prev Close
1.42
Price
1.42
Change %
0.00%
Consensus
Buy
Avg. Price Target
$10.29
Implied Upside
+624.6%
Analysts11incl. previous ratings
Rating Distribution8 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 31, 2026Downgrade
GGuggenheim
Buy → Neutral
Aug 11, 2026Downgrade
EVR logoEEvercore ISI
Outperform → In-line$5+252.1%
Aug 11, 2026Downgrade
CChardan Capital Markets
Buy → Neutral$5+252.1%
Jul 28, 2026Initiated
CCanaccord Genuity
Buy$35+2,364.8%
Jul 22, 2026Initiated
EVR logoEEvercore ISI
Outperform$39+2,646.5%
Jun 22, 2026Initiated
CChardan Capital Markets
Buy$27+1,801.4%
Mar 17, 2026Initiated
CCantor Fitzgerald
Overweight$35+2,364.8%
Sep 08, 2025Initiated
PPiper Sandler
Overweight$20+1,308.5%
Oct 24, 2024Initiated
LLeerink Partners
Outperform$16+1,026.8%
Oct 14, 2024Initiated
GGuggenheim
Buy$16+1,026.8%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ADAR1 Capital Management, LLC10% OwnerOct 21 '26Buy1.66331,979550,6877,447,000Oct 21 04:49 PM
ADAR1 Capital Management, LLC10% OwnerOct 19 '26Buy1.51336,528507,0136,860,679Oct 21 04:49 PM
ADAR1 Capital Management, LLC10% OwnerOct 20 '26Buy1.60254,342405,7267,115,021Oct 21 04:49 PM
Doogan DeclanDirectorSep 16 '26Buy1.9253,000101,76055,274Sep 17 09:30 PM
Giordano Christopher ThomasCEOSep 11 '26Buy1.886,00011,25017,324Sep 15 09:38 PM
Giordano Christopher ThomasCEOSep 15 '26Buy1.824,8508,83722,174Sep 15 09:38 PM
STAAB THOMAS R IIChief Financial OfficerSep 11 '26Buy1.945,67510,98115,675Sep 15 09:30 PM
ADAR1 Capital Management, LLC10% OwnerSep 03 '26Buy1.78900,0001,604,1606,524,151Sep 08 05:16 PM
ADAR1 Capital Management, LLC10% OwnerAug 31 '26Buy1.79403,571722,5945,257,389Sep 02 05:52 PM
ADAR1 Capital Management, LLC10% OwnerSep 02 '26Buy1.80187,704337,5865,624,151Sep 02 05:52 PM
ADAR1 Capital Management, LLC10% OwnerSep 01 '26Buy1.80179,058321,5705,436,447Sep 02 05:52 PM
ADAR1 Capital Management, LLC10% OwnerAug 21 '26Buy1.77716,3691,266,2544,746,444Aug 24 06:12 PM
ADAR1 Capital Management, LLC10% OwnerAug 20 '26Buy1.78202,124359,5384,030,075Aug 24 06:12 PM
ADAR1 Capital Management, LLC10% OwnerAug 24 '26Buy1.75107,374188,3554,853,818Aug 24 06:12 PM
Giordano Christopher ThomasCEOJul 13 '26Option Exercise5.888,71951,26711,324Jul 14 07:29 PM
Rich StuartChief Medical OfficerDec 09 '25Buy10.222,50025,5425,266Dec 10 06:48 PM
Rich StuartChief Medical OfficerDec 08 '25Buy10.102,50025,2505,000Dec 10 06:48 PM
Rich StuartChief Medical OfficerDec 04 '25Buy9.202,50022,9982,500Dec 05 05:46 PM
Rich StuartChief Medical OfficerDec 03 '25Buy9.081,50013,6182,766Dec 05 05:46 PM
Rich StuartChief Medical OfficerDec 02 '25Buy9.011,0009,0061,266Dec 05 05:46 PM
Giordano Christopher ThomasCEONov 20 '25Buy7.595384,0832,605Nov 20 06:38 PM
Giordano Christopher ThomasCEONov 19 '25Buy7.514553,4172,067Nov 20 06:38 PM
Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.
CEOMr. Christopher T. Giordano
Principal Financial Officer & Principal Accounting OfficerMr. Thomas A. McGauley
Chief Medical Officer & DirectorDr. Stuart Rich M.D.
CPAMr. Thomas R. Staab II
Chief Business OfficerMr. Doug Randall